Impact of biological and non-biological treatment on hematological indices in patients with ankylosing spondylitis and psoriatic arthritis

Egyptian Rheumatology and Rehabilitation

Table 6 Comparison between different types of biologics in AS as regards WBCs, RBCs, and platelets indices

AS	Biologics						t test
	Golimumab			Secukinumab			t	P value
	Mean	±	SD	Mean	±	SD	t	P value
WBCS	5.950	±	1.769	6.828	±	2.173	− 1.090	0.286
Neutrophils	3.420	±	1.227	4.078	±	1.769	− 1.041	0.308
Lymphocytes	2.140	±	0.655	2.306	±	0.790	− 0.563	0.579
HCT	39.290	±	2.983	38.261	±	2.876	0.895	0.379
RBCs	5.020	±	0.547	5.006	±	0.748	0.053	0.958
Hb	13.40	±	1.627	13.150	±	1.853	0.356	0.724
MCV	82.01	±	6.748	76.539	±	8.904	1.687	0.104
MCH	25.800	±	3.883	24.972	±	4.175	0.515	0.611
RDW%	12.470	±	0.970	12.317	±	1.335	0.318	0.753
PLT	286.5	±	127.8	336.6	±	167.4	− 0.82	0.419
MPV/fl	10.21	±	3.67	9.772	±	2.87	0.350	0.729
PDW	10.65	±	2.19	11.99	±	3.1	− 1.21	0.239
Hb/PLT ratio	0.053	±	0.02	0.048	±	0.02	0.614	0.545
RDW%/PLT ratio	0.050	±	0.02	0.044	±	0.02	0.841	0.408
RBCs/PLT ratio	0.020	±	0.01	0.019	±	0.01	0.419	0.679
Hb/RDW% ratio	1.084	±	0.18	1.079	±	0.19	0.063	0.950
Neutrophil/lymphocyte ratio	1.651	±	0.59	1.956	±	1.26	− 0.72	0.478
PLT/lymphocyte ratio	142.7	±	64.9	156.1	±	68.2	− 0.51	0.618

AS ankylosing spondylitis, DD disease duration, WBCs white blood cells, HCT hematocrit, RBCs red blood cells, HB hemoglobin, MCV mean corpuscular volume, MCH mean corpuscular hemoglobin, RDW red cell distribution width, PLT platelet, MPV mean platelet volume, PDW platelet distribution width, SD standard deviation. Level of significance: P ≤ 0.05: significant, P < 0.005: highly significant